Armistice Capital’s BioXcel Therapeutics BTAI Stock Holding History

Armistice Capital’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.56M	Buy	+1,910,076	New	+$3.15M	0.05%	151
2025 Q1	–	Sell	-269,688	Closed	-$1.61M	–	236
2024 Q4	$1.61M	Buy	+269,688	New	+$2.25M	0.02%	160
2024 Q3	–	Sell	-186,688	Closed	-$3.82M	–	268
2024 Q2	$3.82M	Buy	186,688 +163,502	+705%	+$5.47M	0.05%	126
2024 Q1	$1.05M	Buy	+23,186	New	+$1.11M	0.01%	161

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital's BTAI Position: Q1 2026 in Review

Armistice Capital opened a new position in BioXcel Therapeutics (BTAI) in Q1 2026: 1,910,076 shares worth $2.56M. The stake represents 0.05% of the portfolio and ranks #151 among its holdings. This is a return to the name: Armistice Capital previously reported a position in BTAI as recently as Q4 2024.

Armistice Capital first reported a position in BTAI in Q1 2024 and has held it in 4 quarters since. The position peaked at $3.82M in Q2 2024. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

Armistice Capital held 1,910,076 shares of BioXcel Therapeutics worth $2.56M as of Q1 2026.
BioXcel Therapeutics was a new Armistice Capital position in Q1 2026.
BioXcel Therapeutics made up 0.05% of Armistice Capital's portfolio in Q1 2026, its #151 holding.
Armistice Capital first reported a position in BioXcel Therapeutics in Q1 2024 and has held it in 4 quarters since.
Armistice Capital's BioXcel Therapeutics position peaked at $3.82M in Q2 2024.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.